ANAPHYLATOXINS IN DILATED CARDIOMYOPATHY

被引:5
|
作者
SAMSONOV, M [1 ]
NASSONOV, E [1 ]
MASENKO, V [1 ]
NAUMOV, V [1 ]
MAREEV, V [1 ]
BELENKOV, Y [1 ]
机构
[1] CARDIOL RES CTR,INST CARDIOL,CLIN IMMUNOL LAB,MOSCOW,RUSSIA
关键词
ANAPHYLATOXINS; DILATED CARDIOMYOPATHY; THROMBOEMBOLIC COMPLICATIONS;
D O I
10.1111/j.1365-2796.1993.tb00722.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objects. The aim of the study was to investigate the possible relationship between activation of complement system and thromboembolic complications in dilated cardiomyopathy (DCMP). Methods. The plasma C3a and C5a concentrations were determined by radioimmunoassay measurement (Amersham International, UK) in 23 patients with DCMP, 9 with hypertrophic cardiomyopathy (HCMP) and 11 healthy volunteers. Results. The mean C3a concentration was significantly higher in DCMP patients (5 72 +/- 55 ng ml-1) compared with hypertrophic cardiomyopathy (344 +/- 30 ng ml-1) and with healthy controls (294 +/- 43 ng ml-1) (P<0.001). There were no significant correlations for C5a concentrations in this group. Mean C3a concentration in DCMP patients with thromboembolic complications (736 +/- 95 ng ml-1) was also significantly higher compared with DCMP patients without these complications (344 +/- 14 ng ml-1) (P<0.001). Conclusions. We conclude that anaphylatoxins may play a role in the pathogenesis of thromboembolic complications.
引用
收藏
页码:139 / 142
页数:4
相关论文
共 50 条
  • [1] DILATED CARDIOMYOPATHY
    DUSLEAG, J
    MEDIZINISCHE WELT, 1995, 46 (10): : 466 - 475
  • [2] Shared Genetic Etiology of Primary Dilated Cardiomyopathy and Ischemic Dilated Cardiomyopathy
    Sun, Yang
    Xiao, Lei
    Li, Ke
    Wang, Hong
    Song, Xiuli
    Li, Zongzhe
    Li, Chenze
    Chen, Yanghui
    Li, Shiyang
    Huang, Jin
    Tan, Lun
    Hu, Dong
    Yu, Ting
    Li, Rui
    Wang, Hong
    Jin, Li
    Shi, Leming
    Marian, Ali J.
    Wang, Dao Wen
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [3] Familial dilated cardiomyopathy
    Osterziel, KJ
    Hassfeld, S
    Geier, C
    Perrot, A
    HERZ, 2005, 30 (06) : 529 - 534
  • [4] Genetics of Dilated Cardiomyopathy
    Yiwen Fu
    Howard J. Eisen
    Current Cardiology Reports, 2018, 20
  • [5] Immunohistochemistry in dilated cardiomyopathy
    Kuhl, U
    Noutsias, M
    Schultheiss, HP
    EUROPEAN HEART JOURNAL, 1995, 16 : 100 - 106
  • [6] Pharmacotherapy of Dilated Cardiomyopathy
    Spinarova, Lenka
    Spinar, Jindrich
    CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (04) : 449 - 458
  • [7] Dilated Cardiomyopathy - An Update
    Meder, B.
    Frese, K. S.
    Katus, H. A.
    AKTUELLE KARDIOLOGIE, 2012, 1 (4-5) : 276 - 280
  • [8] Genetics in dilated cardiomyopathy
    Garcia-Pavia, Pablo
    Cobo-Marcos, Marta
    Guzzo-Merello, Gonzalo
    Gomez-Bueno, Manuel
    Bornstein, Belen
    Lara-Pezzi, Enrique
    Segovia, Javier
    Alonso-Pulpon, Luis
    BIOMARKERS IN MEDICINE, 2013, 7 (04) : 517 - 533
  • [9] Epigenetics in dilated cardiomyopathy
    Yu, Junyi
    Zeng, Chunyu
    Wang, Yibin
    CURRENT OPINION IN CARDIOLOGY, 2019, 34 (03) : 260 - 269
  • [10] A dilated alcoholic cardiomyopathy
    Lamari, Annalisa
    Dattilo, Giuseppe
    Zito, Concetta
    Morabito, Gaetano
    Tulino, Domenico
    Altieri, Tiziana
    Nesci, Bruno
    Marte, Filippo
    Patane, Salvatore
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 149 (03) : E95 - E96